GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mirati Therapeutics Inc (NAS:MRTX) » Definitions » Market Cap

Mirati Therapeutics (Mirati Therapeutics) Market Cap : $4,117.67 Mil (As of Apr. 26, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Mirati Therapeutics Market Cap?

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Mirati Therapeutics's share price for the quarter that ended in Sep. 2023 was $43.56. Mirati Therapeutics's Shares Outstanding (EOP) for the quarter that ended in Sep. 2023 was 70.11 Mil. Therefore, Mirati Therapeutics's market cap for the quarter that ended in Sep. 2023 was $3,054.05 Mil.

Mirati Therapeutics's quarterly market cap declined from Mar. 2023 ($2,163.39 Mil) to Jun. 2023 ($2,107.80 Mil) but then increased from Jun. 2023 ($2,107.80 Mil) to Sep. 2023 ($3,054.05 Mil).

Mirati Therapeutics's annual market cap declined from Dec. 2020 ($11,078.44 Mil) to Dec. 2021 ($8,120.30 Mil) and declined from Dec. 2021 ($8,120.30 Mil) to Dec. 2022 ($2,621.39 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Mirati Therapeutics's Enterprise Value for Today is $3,191.46 Mil.


Mirati Therapeutics Market Cap Historical Data

The historical data trend for Mirati Therapeutics's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mirati Therapeutics Market Cap Chart

Mirati Therapeutics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Market Cap
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,380.30 5,092.20 11,078.44 8,120.30 2,621.39

Mirati Therapeutics Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Market Cap Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4,020.60 2,621.39 2,163.39 2,107.80 3,054.05

Competitive Comparison of Mirati Therapeutics's Market Cap

For the Biotechnology subindustry, Mirati Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mirati Therapeutics's Market Cap Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mirati Therapeutics's Market Cap distribution charts can be found below:

* The bar in red indicates where Mirati Therapeutics's Market Cap falls into.



Mirati Therapeutics Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Mirati Therapeutics's Market Cap for the fiscal year that ended in Dec. 2022 is calculated as

Market Cap (A: Dec. 2022 )=Share Price (A: Dec. 2022 )*Shares Outstanding (EOP) (A: Dec. 2022 )
=$45.31*57.8546
=$2,621.39

Mirati Therapeutics's Market Cap for the quarter that ended in Sep. 2023 is calculated as

Market Cap (Q: Sep. 2023 )=Share Price (Q: Sep. 2023 )*Shares Outstanding (EOP) (Q: Sep. 2023 )
=$43.56*70.1113
=$3,054.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Mirati Therapeutics  (NAS:MRTX) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the company’s debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.


Mirati Therapeutics Market Cap Related Terms

Thank you for viewing the detailed overview of Mirati Therapeutics's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.


Mirati Therapeutics (Mirati Therapeutics) Business Description

Traded in Other Exchanges
Address
3545 Cray Court, San Diego, CA, USA, 92121
Mirati Therapeutics Inc is a clinical-stage oncology company developing novel therapeutics to address the genetic and immunological promoters of cancer. It operates in a single geographical segment being the United States.
Executives
Jamie Christensen officer: Sr. Vice President, Chief Scie C/O MIRATI THERAPEUTICS, INC., 9393 TOWNE CENTRE DRIVE, SUITE 200, SAN DIEGO CA 92121
Benjamin Hickey officer: EVP, Chief Commercial Officer C/O MIRATI THERAPEUTICS, 9393 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA 92121
Aaron Ondrey officer: Interim CFO 3545 CRAY COURT, SAN DIEGO CA 92121
Boxer Capital, Llc other: See remarks 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Christopher Fuglesang other: See remarks 11682 EL CAMINO REAL, SUITE 320, SAN DIEGO CA 92130
Shehan Bharatha Dissanayake other: See remarks 11682 EL CAMINO REAL, SUITE 320, SAN DIEGO CA 92130
Aaron I. Davis other: See remarks 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Mva Investors, Llc other: See remarks 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Boxer Asset Management Inc. other: See remarks CAY HOUSE, EP TAYLOR DRIVE N7776, LYFORD CAY, NEW PROVIDENCE C5 00000
Joseph Lewis other: See remarks PO BOX N7776, LYFORD BAHAMAS
Faheem Hasnain director 14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
John B Moriarty officer: Chief Legal Officer ALEXION PHARMACEUTICALS, 352 KNOTTER DRIVE, CHESHIRE CT 06410
Carol Giltner Gallagher director C/O ATARA BIOTHERAPEUTICS, INC., 3260 BAYSHORE BOULEVARD, BRISBANE CA 94005
Laurie Stelzer officer: CFO 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Julie M Cherrington director 9393 TOWNE CENTRE DRIVE, STE 200, SAN DIEGO CA 92121

Mirati Therapeutics (Mirati Therapeutics) Headlines